The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
The findings support the fact that further extension of nationwide cardiovascular disease (CVD) risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases are warranted
Merzee is a generic equivalent of Taytulla of Allergan Pharmaceuticals International
With this move, government hospitals across India can now access the geko device to prevent life-threatening blood clots, and address complications related to swelling following orthopaedic surgery and the healing of chronic wounds (leg ulcers)
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East
The new reagents will bring the exceptional sensitivity of the company’s liquid format 1-step RT-qPCR reagents to a freeze-dryable format
Ind-Ra maintains a neutral outlook for healthcare in FY23
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Subscribe To Our Newsletter & Stay Updated
